Presumed topiramate-induced maculopathy.
The case of a patient who developed decreased vision while taking topiramate (TPM) for symptomatic epilepsy is described. Ophthalmological examination revealed findings suggestive of maculopathy. TPM was discontinued; however, vision failed to improve significantly over 6 months of follow-up. We hypothesize that the patient's maculopathy was induced by TPM. TPM, like vigabatrin, may exert retinal toxicity causing persistent visual impairment.
Beyenburg
Stefan
S
Service de Neurologie, Centre Hospitalier de Luxembourg, Rue Barblé 4, L-1210 Luxembourg, Luxembourg. beyenburg.stefan@chl.lu
Weyland
Christophe
C
Reuber
Markus
M
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D002533:Cerebral Angiography; D004569:Electroencephalography; D004829:Epilepsy, Generalized / Q000150:complications / Q000188:drug therapy; D005260:Female; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008268:Macular Degeneration / Q000139:chemically induced*; D008279:Magnetic Resonance Imaging; D000077236:Topiramate; D014787:Vision Tests
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose